Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 1681 AL 1695

Decision-making impairments in Parkinson's disease as a by-product of defective cost-benefit analysis and feedback processing

Ryterska A, Jahanshahi M, Osman M.

Neurodegener Dis Manag. 2014;4(4):317-27. doi: 10.2217/nmt.14.23.

Managing depression in Parkinson's patients: risk factors and clinical pearls

Biemiller R, Richard IH.

Neurodegener Dis Manag. 2014;4(4):329-36. doi: 10.2217/nmt.14.31.

RETRACTED: Efficacy of bisphosphonates against hip fracture in elderly patients with stroke and Parkinson diseases: meta-analysis of randomized controlled trials

Zhang W, Zhu C, Sun M, Ge Y, Yan G.

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2714-2724. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.022. Epub 2014 Oct 12.

Driving neural regeneration through the mammalian target of rapamycin

Maiese K.

Neural Regen Res. 2014 Aug 1;9(15):1413-7. doi: 10.4103/1673-5374.139453.

The role of DJ-1 in the oxidative stress cell death cascade after stroke

Pantcheva P, Elias M, Duncan K, Borlongan CV, Tajiri N, Kaneko Y.

Neural Regen Res. 2014 Aug 1;9(15):1430-3. doi: 10.4103/1673-5374.139458.

New treatments for the motor symptoms of Parkinson's disease

Vijverman AC, Fox SH.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):761-77. doi: 10.1586/17512433.2014.966812.

Cognitive and sleep features of multiple system atrophy: review and prospective study

Stanzani-Maserati M, Gallassi R, Calandra-Buonaura G, Alessandria M, Oppi F, Poda R, Sambati L, Provini F, Cortelli P.

Eur Neurol. 2014;72(5-6):349-59. doi: 10.1159/000364903. Epub 2014 Oct 14.

Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease

McCormack PL.

CNS Drugs. 2014 Nov;28(11):1083-97. doi: 10.1007/s40263-014-0206-y.

A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends

Butt DA, Tu K, Young J, Green D, Wang M, Ivers N, Jaakkimainen L, Lam R, Guttman M.

Neuroepidemiology. 2014;43(1):28-37. doi: 10.1159/000365590. Epub 2014 Oct 16.

RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders

Canal M, Romaní-Aumedes J, Martín-Flores N, Pérez-Fernández V, Malagelada C.

Front Cell Neurosci. 2014 Oct 2;8:313. doi: 10.3389/fncel.2014.00313. eCollection 2014.

Hyperhomocysteinemia and neurologic disorders: a review

Ansari R, Mahta A, Mallack E, Luo JJ.

J Clin Neurol. 2014 Oct;10(4):281-8. doi: 10.3988/jcn.2014.10.4.281. Epub 2014 Oct 6.

Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease

Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijselinck I, Smolders S, Crosiers D, Corsmit E, Elinck E, Sharma M, Krüger R, Lesage S, Brice A, Chung SJ, Kim MJ, Kim YJ, Ross OA, Wszolek ZK, Rogaeva E, Xi Z, Lang AE, Klein C, Weissbach A, Mellick GD, Silburn PA, Hadjigeorgiou GM, Dardiotis E, Hattori N, Ogaki K, Tan EK, Zhao Y, Aasly J, Valente EM, Petrucci S, Annesi G, Quattrone A, Ferrarese C, Brighina L, Deutschländer A, Puschmann A, Nilsson C, Garraux G, LeDoux MS, Pfeiffer RF, Boczarska-Jedynak M, Opala G, Maraganore DM, Engelborghs S, De Deyn PP, Cras P, Cruts M, Van Broeckhoven C; GEO-PD Consortium.

Neurology. 2014 Nov 18;83(21):1906-13. doi: 10.1212/WNL.0000000000001012. Epub 2014 Oct 17.

Mind matters: placebo enhances reward learning in Parkinson's disease

Schmidt L, Braun EK, Wager TD, Shohamy D.

Nat Neurosci. 2014 Dec;17(12):1793-7. doi: 10.1038/nn.3842. Epub 2014 Oct 19.

[Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes]

Salvador J, Andrada P.

Med Clin (Barc). 2014;143 Suppl 2:28-34. doi: 10.1016/S0025-7753(14)70106-X.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias